Pharmaceutical Technology on MSN
FDA approves Regeneron’s Libtayo for high-risk CSCC post-surgery
The US Food and Drug Administration (FDA) has granted approval to Regeneron Pharmaceuticals’ fully human monoclonal antibody ...
Libtayo gained FDA approval as the first immunotherapy for high-risk cutaneous squamous cell carcinoma, promising improved ...
The world's largest randomised trial of potential medicines for COVID-19 is to add Regeneron's experimental antiviral antibody cocktail REGN-COV2 to the drugs it is testing in patients hospitalised ...
Investing.com -- Regeneron Pharmaceuticals (NASDAQ:REGN) stock rose 2% Wednesday following the FDA’s approval of its drug Libtayo for the adjuvant treatment of adults with cutaneous squamous cell ...
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.
Regeneron's Libtayo has become the first checkpoint inhibitor to be cleared by the FDA as an adjuvant treatment for adults ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the most promising biotech stocks to buy according to hedge funds.
Regeneron Pharmaceuticals is seeing revenue growth in key products that is now offsetting declining revenue in its previous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback